Related Experiment Video
Updated: May 8, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Large Hemorrhagic Pericardial Effusion and Cardiac Tamponade Following BNT162b2 (BioNTech/Pfizer) Vaccine
Hien Nguyen1, Michelle Nguyen1, Angela Olenik1
1Department of Internal Medicine Camp Springs Medical Center, Kaiser Permanente, Temple Hills, MD, USA.
Abstract:
The introduction of mRNA-based COVID-19 vaccinations has been useful in decreasing risks of severe illness with COVID-19 infection. Cardiac tamponade is a rare cardiovascular emergency that has been observed following both mRNA-based COVID-19 vaccinations and COVID-19 infections. We report the first case of a hemorrhagic pericardial effusion with cardiac tamponade in a 52-year-old woman occurring one week following the second dose of the BNT162b2 (BioNTech/Pfizer) SARS-CoV-2 vaccination. The time sequence in this case report correlates with reports submitted to the Vaccine Adverse Event Reporting System (VAERS), which indicates that cases of pericarditis following mRNA vaccination most commonly occur within 1-2 weeks following the second dose of vaccination.
Related Concept Videos
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pericarditis I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests
Pericarditis III: Medical Management
Pericarditis IV: Nursing Management
Cardiomyopathy II: Dilated Cardiomyopathy

